Stockscreener 앱 받기
5.79
0.61%
0.035
시간 외 거래:
5.51
-0.28
-4.84%
전일 마감가:
$5.755
열려 있는:
$5.66
하루 거래량:
635.11K
Relative Volume:
0.56
시가총액:
$422.60M
수익:
$531.00K
순이익/손실:
$-104.97M
주가수익비율:
-2.1431
EPS:
-2.7017
순현금흐름:
$-107.19M
1주 성능:
-12.67%
1개월 성능:
-7.66%
6개월 성능:
+12.43%
1년 성능:
+90.46%
1일 변동 폭
$5.50
$5.91
1주일 범위
$5.50
$6.99
52주 변동 폭
$1.45
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
명칭
Lexeo Therapeutics Inc
전화
(212) 547-9879
주소
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
5.79 | 420.04M | 531.00K | -104.97M | -107.19M | -2.7017 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Raymond James | Strong Buy |
| 2025-11-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-10-15 | 개시 | Guggenheim | Buy |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2024-06-13 | 개시 | Robert W. Baird | Outperform |
| 2024-06-06 | 개시 | H.C. Wainwright | Buy |
| 2023-11-28 | 개시 | Chardan Capital Markets | Buy |
| 2023-11-28 | 개시 | JP Morgan | Overweight |
| 2023-11-28 | 개시 | Leerink Partners | Outperform |
| 2023-11-28 | 개시 | RBC Capital Mkts | Outperform |
| 2023-11-28 | 개시 | Stifel | Buy |
모두보기
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
Lexeo Therapeutics (LXEO) CEO acquires 2,623 shares via employee stock plan - Stock Titan
Signal Recap: Can Lexeo Therapeutics Inc ride the EV waveMarket Trend Summary & Proven Capital Preservation Methods - baoquankhu1.vn
LEXEO THERAPEUTICS Q4 2025 Earnings Preview: Recent $LXEO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
LXEO Stock Chart | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 10.4%What's Next? - MarketBeat
Sectors Review: Is Lexeo Therapeutics Inc. subject to activist investor interestWeekly Trade Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Is Lexeo Therapeutics Inc a cyclical or defensive stockMarket Volume Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Wall Street rallies behind Lexeo Therapeutics (LXEO)’s gene therapy pipeline - MSN
Published on: 2026-03-07 09:09:20 - baoquankhu1.vn
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference - The Manila Times
Nasdaq Moves: Can Lexeo Therapeutics Inc ride the EV waveRate Cut & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference - MarketBeat
Cantor Fitzgerald Remains a Buy on Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
LXEO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings Update: Is Lexeo Therapeutics Inc forming a bullish divergenceProduct Launch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Profit Review: Is Lexeo Therapeutics Inc forming a bullish divergenceShare Buyback & Risk Controlled Stock Alerts - baoquankhu1.vn
Narinder Pal Bhalla Net Worth (2026) - GuruFocus
Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $64,903.74 in Stock - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) COO Sells $19,302.40 in Stock - Defense World
Will Lexeo Therapeutics Inc. outperform its industry peersEarnings Risk Summary & Capital Efficient Trade Techniques - mfd.ru
Balyasny Asset Management L.P. Increases Stake in Lexeo Therapeu - GuruFocus
Top Brass at Biotech Player Quietly Cash Out in Latest Insider Move - TipRanks
Balyasny Asset Management L.P. Increases Stake in Lexeo Therapeutics Inc. - GuruFocus
LXEO (NASDAQ: LXEO) affiliate plans sale of 4,867 vested shares - Stock Titan
LXEO (NASDAQ: LXEO) Form 144 reports 3,861 shares tied to vesting - Stock Titan
LXEO Should I Buy - Intellectia AI
Citadel discloses 7.4% Lexeo Therapeutics (LXEO) ownership in 13G/A - Stock Titan
BioAgilytix Labs, Inc Receives FDA Breakthrough Device Designation for Anti-AAV Antibody Assay - The Courier-Journal
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-02-16 16:57:11 - baoquankhu1.vn
Is Lexeo Therapeutics Inc. still a buy after recent gainsJuly 2025 Earnings & Fast Entry Momentum Trade Alerts - mfd.ru
Lexeo Therapeutics Details FDA Path for LX2006, Highlights LVMI Gains at Guggenheim Biotech Summit - MarketBeat
A | Does Lexeo Therapeutics, Inc. have declining or rising EPSPortfolio Update Report & Weekly Watchlist of Top Performers - mfd.ru
Page not foundAirwhon - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Down 3.2%Time to Sell? - MarketBeat
Will Lexeo Therapeutics Inc. announce a stock splitJuly 2025 Spike Watch & Smart Allocation Stock Reports - mfd.ru
Volatility Watch: Is Lexeo Therapeutics Inc backed by strong institutional buyingPortfolio Return Report & Low Risk High Reward Ideas - baoquankhu1.vn
Lexeo Therapeutics Announces Head of Research Transition - The Globe and Mail
Lexeo Therapeutics (LXEO) CFO receives RSUs and 226,665-share stock option - Stock Titan
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - 富途牛牛
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program - Yahoo Finance
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)'s PKP2 Program - Finviz
Lexeo TherapeuticsRevolutionizing Heart Health With Gene Therapies - RTTNews
Lexeo Therapeutics Announces Key Executive Leadership Changes - The Globe and Mail
Lexeo Therapeutics Announces Key Leadership Appointments - citybiz
Lexeo Therapeutics appoints new COO and CMO, announces executive transition - Investing.com Nigeria
Lexeo Therapeutics appoints new COO and CMO, announces executive transition By Investing.com - Investing.com South Africa
Lexeo Therapeutics Inc (LXEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):